Meet the Marinus Team

Marinus Pharmaceuticals’ management team is committed to developing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders in both the hospital and home setting.

Leadership

Scott Braunstein 2

Scott Braunstein, M.D.

Chief Executive Officer & Director

Scott Braunstein, M.D. was appointed Chief Executive Officer of Marinus in August 2019, executive chairman in February 2019 and has served on our Board since September 2018.

Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. Dr. Braunstein is currently an operating partner at Aisling Capital. He most recently served as chief strategy officer and chief operating officer at Pacira Pharmaceuticals, Inc. Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 13 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as portfolio manager of the JP Morgan Global Healthcare Fund responsible for managing investments in pharmaceuticals, biotechnology and medical devices.

Dr. Braunstein is currently on the board at Trevena Inc., Ziopharm Oncology Inc. and Constellation Pharmaceuticals. He previously served as board member of Esperion Pharmaceuticals and Protara Theraputics Inc. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine.

Scott Braunstein 2

Scott Braunstein, M.D.

Chief Executive Officer & Director

 

Edward Smith

Edward F. Smith

Vice President, Chief Financial Officer and Treasurer

Edward F. Smith has more than 20 years of executive finance and operational leadership experience in publicly traded biotechnology companies from early stage through commercial stage.

As CFO of Marinus, Mr. Smith oversees finance, accounting, information technology, and program management. Throughout his career, he has raised hundreds of millions of dollars from IPOs, follow-on equity raises, private placements, convertible securities, and debt issuances. Prior to Marinus, Mr. Smith served as CFO of PolyMedix, Inc., and executive director of finance at InKine Pharmaceutical Company, Inc., where he assisted with the acquisition of the company by Salix Pharmaceuticals, Inc. Earlier in his career, he held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte & Touche, LLP.

Mr. Smith is currently a member of the board of directors at Benitec Biopharma, Inc., a development-stage biotechnology company focused on the advancement of novel genetic medicines. Mr. Smith holds a B.S. in business administration from the University of Hartford and was licensed as a Certified Public Accountant in Pennsylvania.

Edward Smith

Edward F. Smith

Vice President, Chief Financial Officer and Treasurer

 

Joe Houlihan 2

Joseph Hulihan, M.D.

Chief Medical Officer

Joseph Hulihan, M.D. brings close to 30 years of experience in clinical drug development, medical affairs and research in numerous conditions in neurology and psychiatry including epilepsy, ADHD, schizophrenia and mood disorders.  

Dr. Hulihan is a board-certified neurologist and clinical neurophysiologist. He spent 15 years at Johnson & Johnson in roles of increasing responsibility with a primary focus on neurology and psychiatry. Most recently he served as Global Medical Affairs Leader, Neuroscience (mood disorders) at Janssen Global Services, LLC. Other roles included Vice President, CNS Medical Affairs at Janssen and Director, CNS Research, Clinical Affairs at Ortho-McNeil Pharmaceutical. Additionally, he was principal at Paradigm Neuroscience, where he provided consulting services including clinical and strategic support for neurotherapeutics in all phases of development.

Dr. Hulihan has served as a principal investigator, member of the clinical development team, group supervisor, and study physician on more than 25 late-stage CNS focused clinical trials and authored more than 70 published papers. He received his medical degree from Drexel University School of Medicine, with Honors in Neurology.

Joe Houlihan 2

Joseph Hulihan, M.D.

Chief Medical Officer

 

Martha Manning Esq

Martha Manning, Esq.

Vice President, General Counsel and Secretary

Martha Manning has spent over 20 years in the life sciences sector, providing legal advice for development stage and commercial biopharma companies.

Immediately prior to joining Marinus, Ms. Manning was Executive Vice President, General Counsel, and Secretary for Achillion Pharmaceuticals, Inc., where she helped to develop and execute corporate strategy, managed corporate governance for the Board of Directors, and handled all legal and compliance matters. Before her tenure at Achillion, she was General Counsel for ICeutica Inc. where she was also responsible for all legal matters, including supporting corporate growth through R&D, product and clinical development, and out licensing.

Ms. Manning has held roles that have included Chief Legal Officer for OraPharma, Inc., Vice President and General Counsel for Sandoz, Inc. (Novartis), Senior Vice President, General Counsel and Secretary for Adolor Corporation, and Business and Finance Associate for the law firm Morgan Lewis & Bockius. Ms. Manning earned her Juris Doctor degree from the University of Pennsylvania Law School and her Bachelor of Business Administration from the University of Massachusetts. She is a member of the Pennsylvania Bar.

Martha Manning Esq

Martha Manning, Esq.

Vice President, General Counsel and Secretary